The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This randomized controlled trial investigates the effect of a single dose of glucagon-like
peptide-1 (GLP-1) receptor agonist in the subacute phase of stroke in humans. The primary
endpoint is the mean flow velocity in the middle cerebral arteries measured by transcranial
doppler and cortical oxygination measured by near infrared spectroscopy (NIRS). The secondary
endpoints are changes in endothelial/inflammatory biomarkers in the blood, changes in the
ankle-brachial index and changes in the reactive hyperaemia index measured by EndoPAT2000.